Teriparatide (Forsteo) is recombinant parathyroid hormone and should be considered for treatment of osteoporosis in postmenopausal women who are intolerant or unresponsive to bisphosphonate therapy and are at very high risk of further fracture.
Current maximum treatment period is 18 months.
|250mcg/ml prefilled pen||20mcg once dailys.c. injection||£271.88 for 1x2.4ml|
Page last updated: 24 November 2011